Skip to main content
Events

DERI Seminar with Dr Mohamed Elbadawi, Lecturer in Computational Physiology/Biomedicine

When: Thursday, February 22, 2024, 11:00 AM - 12:00 PM
Where: Zoom

Speaker: Dr Mohamed Elbadawi, Lecturer in Computational Physiology/Biomedicine, QM

Title:  Artificial Intelligence Generates Novel 3D Printing Formulations

Zoom link: https://qmul-ac-uk.zoom.us/j/81148100921

Abstract
Formulation development is a critical step in the development of medicines. The process requires human creativity, ingenuity and in-depth knowledge of formulation development and processing optimization, which can be time-consuming. Herein, we tested the ability of artificial intelligence (AI) to create de novo formulations for three-dimensional (3D) printing. Specifically, conditional generative adversarial networks (cGANs), which are generative models known for their creativity, were trained on a dataset consisting of 1437 fused deposition modelling (FDM) printed formulations that were extracted from both the literature and in-house data. In total, 27 different cGANs architectures were explored with formulations. After a comparison between the characteristics of AI-generated and human-generated formulations, it was discovered that cGANs with a medium learning rate (10-4) could strike a balance in generating formulations that are both novel and realistic. Four of these formulations were fabricated using an FDM printer, of which the first AI-generated formulation was successfully printed. Our study represents a milestone, highlighting the capacity of AI to undertake creative tasks and its potential to revolutionize the drug development process. 

Bio
Moe is a recently appointed Lecturer in Computational Physiology/Biomedicine, at the School of Biological and Behavioural Sciences. His research focuses on the use of digital technologies for advancing medicine development, such as 3D printing, AI and bioelectronics. Prior to QMUL, Moe was a postdoctoral Fellow at UCL on the Integrated Research Centre in Targeted Delivery for hard-to-treat Cancers, which was spearheaded by the University of Cambridge. Prior to that, he had spent two years as a Postdoctoral researcher in the department of Computer Science, Electrical and Space Engineering at LTU, Sweden. 

 

 

 

Back to top